AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

HOSPITALS have been hit by a “highly infectious” winter vomiting bug which experts have warned you can catch more than once. Norovirus cases are continuing to soar with new NHS data ...

Be it from tap water on a vacation, some dodgy chicken, or something the kids have brought home from school, we've almost all been flattened by an awful stomach bug at some point in our lives. For ...

BRITS are being urged to stay at home and mask up when venturing outside after a “worrying” surge in norovirus cases. While ...

Norovirus, also known as the winter vomiting bug, is currently seeing a surge in infections with rates twice as high as previous years. In Wales cases of the virus were up 12% this winter compared ...

Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...

Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Evercore ISI from $60.00 to $50.00 in a research ...

Lehigh Valley’s health networks are seeing abnormally high cases of the stomach bug that’s taking a large number of people ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.